公开(公告)号：US20170369592A1

公开(公告)日：2017-12-28

申请号：US15541998

申请日：2016-01-11

申请人： Mabimmune Diagnostics AG ,  Neurimmune Holding AG ,  University of Zurich

发明人： Chad BROKOPP ,  Jan GRIMM ,  Benoit COMBALUZIER ,  Mareike GOERANSON ,  Christine LOHMANN ,  Simon HOERSTRUP ,  Roger NITSCH

IPC分类号： C07K16/40 ,  G01N33/573 ,  A61K47/68 ,  C12N9/48 ,  C07K16/28 ,  G01N33/574

CPC分类号： C07K16/40 ,  A61K47/6871 ,  A61K2039/505 ,  C07K16/2878 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C12N9/485 ,  C12Y304/14005 ,  G01N33/573 ,  G01N33/57492 ,  G01N2333/948 ,  G01N2800/224 ,  G01N2800/226 ,  G01N2800/323 ,  G01N2800/52

摘要： Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.

公开(公告)号：US20180022822A1

公开(公告)日：2018-01-25

申请号：US15648246

申请日：2017-07-12

申请人： Mabimmune Diagnostics AG

发明人： Chad BROKOPP ,  Jan Grimm ,  Benoit Combaluzier ,  Manuel Tobias Gersbacher

IPC分类号： C07K16/40 ,  C07K14/705 ,  C07K14/725

CPC分类号： C07K16/40 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70575 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/70 ,  C07K2319/74 ,  C12Y304/14005

摘要： Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, and chimeric antigen receptors (CARs) directed against the human FAP antigen as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.